Cher­ry Thomas joins Cari­bou as SVP of clin­i­cal de­vel­op­ment; Ar­tax locks in Joseph Lobac­ki as CEO

→ CRISPR genome edit­ing play­er Cari­bou Bio­sciences has ap­point­ed Cher­ry Thomas as SVP of clin­i­cal de­vel­op­ment, a new­ly-cre­at­ed po­si­tion. Thomas jumps to Berke­ley-based Cari­bou from Ar­ray Bio­phar­ma, where she was VP of clin­i­cal de­vel­op­ment of their on­col­o­gy di­vi­sion. She’s al­so been the ex­ec­u­tive di­rec­tor of clin­i­cal de­vel­op­ment at BeiGene.

→ Not on­ly has au­toim­mune dis­ease-fo­cused Ar­tax Bio­phar­ma brought Joseph Lobac­ki to the helm as CEO, but the Cam­bridge, Mass­a­chu­setts-based com­pa­ny has al­so made some new ad­di­tions to its man­age­ment team. Lobac­ki takes over the reins from Damia Tor­mo, who re­mains on the com­pa­ny’s board of di­rec­tors. Lobac­ki joins the team af­ter a stint at Ve­rastem as EVP and CCO and as COO of Finch Ther­a­peu­tics. In ad­di­tion, Lobac­ki has held posts at Medi­va­tion, Mi­cromet and Gen­zyme.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.